TopFunds

Gilead Sciences, Inc.

NASDAQ: GILD

Stock price

134.28 USD

(+Infinity%) NaN day

Drug Manufacturers - General

Financial Performance

Share

5Y price score: 132

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 85.4%

DATE RANGE:

US$ Per
Share

    Time scale:

    By default your notes are visible only to you.

    107.7

    52-week range

    157.2

    134.28

    Your model inputs

    Required return / cost of capital
    %
    FCFF terminal growth rate
    %

    Your fair value & Margin of safety

    To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

    Forecast:

    Valuation

    Free Cash Flow Yield

    Help
    FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

    6.1 %

    Dividend Yield TTM

    2.4 %

    Market cap $

    $ 166,718

    Price / Earnings TTM

    Help
    P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

    18.3

    Price / Book TTM

    7.1

    PEG TTM

    Help
    Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

    0

    Earnings growth and return

    LTM

    5YR

    10YR

    Total return (price & dividends)

    26.3 %

    117.5 %

    85.4 %

    Free cash flow per share growth

    (8.2) %

    26.6 %

    (44.1) %

    Earnings per share growth

    1,684.2 %

    6,861 %

    (43.1) %

    Founded: 1,987

    Employees: 17,600

    Business Summary:Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

    Fair Value Reference Estimate

    Latest Earnings Call Takeaways

    Annual Reports, Presentations And IR Contacts

    Go to the website
    Annual report links (10K)
    2025202420232022202120202019201820172016

    Gilead Sciences, Inc. — Financial Overview, Stock Price, Market Cap

    Gilead Sciences, Inc. is a company. Founded in 1987. As of July 20, 2026, the company's market capitalization is $166718002681 with a current stock price of $134.28.